Gilead will price its COVID-19 drug, remdesivir, at $390 per vial to ensure broad and equitable access during the global pandemic, according to an official letter from Gilead chairman and CEO, Daniel...
Gilead Sciences recently announced that it will acquire 49.9 percent equity interest in Pionyr Immunotherapeutics Inc with exclusive option for $275 million.
Pionyr, a privately held company...
Abbott and Tandem Diabetes Care (NASDAQ:TNDM) recently announced a finalized agreement to develop and commercialize integrated diabetes management solutions to improve care for patients living...
The World Health Organization (WHO) temporarily paused the use of hydroxychloroquine (HCQ) in its Solidarity trial based on study results which showed the drug was not effective in treating...
New data from real-world evidence suggests that simultaneous insulin and GLP-1 RA therapies could provide more effective blood sugar control in patients with uncontrolled type 2 diabetes.
Researchers...
AbbVie and Genmab recently signed a broad collaboration agreement to jointly develop and commercialize Genmab’s three early-stage investigational antibody therapeutics for cancer.
Genmab...
FDA recently revoked the emergency use authorization (EUA) for the SARS-CoV-2 antibody test, Chembio Diagnostic System (Chembio), due to performance concerns, according to an official press...
AstraZeneca recently partnered with Accent Therapeutics to discover, develop, and commercialize novel cancer therapeutics targeting RNA-modifying proteins (RMPs).
The companies will focus on targeting...
AbbVie recently announced new Phase 3 clinical trial data, showing that RINVOQ (upadacitinib) was effective in adult patients with moderate to severe active rheumatoid arthritis.
SELECT-CHOICE, a...
FDA recently issued guidance to the Institutional Review Board (IRBs) regarding expanded access requests for COVID-19 investigational drugs, including expanded access for individual patients.
For more...
Eli Lilly and Company recently announced that its partner, Junshi Biosciences, dosed the first healthy volunteer in a study of a potential COVID-19 antibody treatment.
For more coronavirus updates,...
A recent study found that the COVID-19 pandemic is associated with a notable decrease in enrollment in National Cancer Institute-sponsored clinical trials for cancer treatments, especially in strongly...
FDA recently approved Eli Lilly’s drug, Tauvid, for intravenous injection, the first drug to help image a specific characteristic of Alzheimer’s disease in the brain called tau...
Moderna recently announced that the first participants in each age cohort have been dosed in the company’s Phase 2 study of two potential COVID-19 vaccines that use its mRNA vaccine candidate,...
HHS recently announced a $628 million task order with Emergent BioSolutions to advance manufacturing capabilities for potential COVID-19 vaccines and therapeutics.
For more coronavirus updates,...
Moderna recently announced positive clinical data for its vaccine candidate, mRNA-1273, from the Phase I study, led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the...
Apple recently announced it awarded $10 million from its Advanced Manufacturing Fund to COPAN Diagnostics to accelerate its supply of COVID-19 supply kits for hospitals across the US.
For more...
An FDA-approved antiviral drug used to treat herpes simplex virus I infection (HSV-1) may be effective for treating plaque formation and other markers of Alzheimer’s disease, according to a new...
Eli Lilly Company and Junshi Biosciences recently entered into an agreement to co-develop COVID-19 antibody therapies for the prevention and treatment of the novel coronavirus.
For more coronavirus...
GSK recently announced that the FDA approved its PARP inhibitor monotherapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in...
